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Abstract
A comprehensive analysis was done to evaluate the potential use of anti-parasitic macrocy-
clic lactones (including avermectins and milbemycins) for Buruli ulcer (BU) therapy. A panel
containing nearly all macrocyclic lactones used in human or in veterinary medicine was ana-
lyzed for activity in vitro against clinical isolates ofMycobacterium ulcerans. Milbemycin
oxime and selamectin were the most active drugs againstM. ulcerans with MIC values from
2 to 8 μg/mL and 2 to 4 μg/mL, respectively. In contrast, ivermectin and moxidectin, which
are both in clinical use, showed no significant activity (MIC> 32 μg/mL). Time-kill kinetic
assays showed bactericidal activity of selamectin and in vitro pharmacodynamic studies
demonstrated exposure-dependent activity. These data together with analyses of published
pharmacokinetic information strongly suggest that selamectin is the most promising macro-
cyclic lactone for BU treatment.
Author Summary
Buruli ulcer (BU) is a chronic debilitating mycobacterial disease of the skin and soft tissue
caused byMycobacterium ulcerans. It is mainly found in tropical regions and often linked
to poverty. BU can be cured in most cases with the standard treatment, a combination of
rifampicin and the injectable antibiotic streptomycin. However, new optimized treatment
regimens are needed, especially to prepare for an eventual development of resistance to
rifampicin, the most efficacious drug for BU therapy. Since traditional antibacterial drug
discovery is not a practical option for BU, using approved drugs for alternative clinical
indications would be a more economical and faster way to implement new anti-BU
therapies. We reported previously that anti-parasitic avermectins are active againstMyco-
bacterium tuberculosis. Here we show that some are also active in vitro against other myco-
bacterial species, includingM.marinum andM. ulcerans. In this study, we undertook a
comprehensive approach to evaluate additional macrocyclic lactones including com-
pounds used in veterinary medicine. Based on our in vitromeasurements of their activities
and a literature review of their pharmacokinetic properties, we present strong arguments
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that selamectin is the avermectin with the highest potential for being repurposed for BU
treatment.
Introduction
Buruli ulcer (BU), caused byMycobacterium ulcerans, is a chronic debilitating disease of the
skin and soft tissue. Although mortality is low, permanent disfigurement and disability is high
[1]. BU is mainly found in Africa, South America and the Western Pacific regions and is often
linked to poverty. If detected early, BU can be cured in most cases with the standard treatment,
a combination of rifampicin and the injectable antibiotic streptomycin [2], without further
adjunct surgical treatment required. However, new treatment regimens are needed to reduce
the long median time to healing, treatment-related side effects, and the requirement for on-site
health care workers to administer injections [3]. Furthermore, an alternative drug treatment
regimen would be required in the event that rifampicin resistantM. ulcerans strains would
emerge in the clinic [4].
Traditionally, the discovery of new antimicrobial drugs has focused on designing and
screening for new compounds having novel targets, an approach that is costly in time and capi-
tal (up to ~$800M and 15–20 years) [5]. This is not a viable option for BU, since most large
pharmaceutical and biotech companies are primarily interested in blockbuster, broad spectrum
antibacterial drugs [6] rather than treatments for neglected tropical diseases. A faster and
cheaper alternative to finding new BU treatments is drug repositioning, i.e. using approved
drugs for alternative clinical indications [7]. These drugs with known pharmacokinetic and
safety profiles could be more rapidly evaluated in clinical trials [8]. Such an approach would
also allow for an easier drug introduction, since manufacturing and distribution infrastructures
are already available.
In the course of screening clinically approved drugs to find new drug combinations for
tuberculosis (TB) therapy, we discovered anti-mycobacterial activities of the avermectins, a
class of macrocyclic lactones [9]. Following up these findings, the in vitro activities of two clini-
cally approved macrocyclic lactones (ivermectin and moxidectin) againstM. ulcerans were
recently reported [10]. The avermectins are a family of macrocyclic lactone derivatives with
potent anthelmintic properties, produced by the soil actinomycete Streptomyces avermitilis.
Since avermectins are inactive against all other bacterial species tested [9], oral administration
would not affect healthful intestinal microbiome balances.
We undertook a comprehensive approach to evaluate additional macrocyclic lactones used
in veterinary medicine. Based on our in vitromeasurements of their activities and a literature
review of their pharmacokinetic (PK) properties, we provide strong indications that selamectin
(used in veterinary medicine), and not ivermectin (used in human medicine), is the avermectin
with the highest potential for clinical efficacy to treat BU.
Materials and Methods
Bacterial strains, general growth conditions and reagents
M.marinum isolates (1704 and 1705; kindly provided by Dr. Julian Davies, University of Brit-
ish Columbia) were routinely propagated at 30°C in Middlebrook 7H9 broth (Difco) supple-
mented with 10%Middlebrook albumin-dextrose-catalase (ADC)(Difco), 0.2% glycerol and
0.05% (vol/vol) Tyloxapol or on Middlebrook 7H10 agar plates (Difco) supplemented with
10% (vol/vol) oleic acid-albumin-dextrose-catalase (OADC)(Difco).M. ulcerans strains S1012,
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S1013 and S1047 (isolated in 2010 and 2011 from Cameroonian BU patients) were routinely
grown in BacT/Alert culture bottles using enrichment medium (bioMérieux) or on Middleb-
rook 7H10 agar plates (Difco) supplemented with 10% (vol/vol) OADC. Macrocyclic lactones
were purchased from the following providers: abamectin and doramectin (Sigma), emamectin
and eprinomectin (LKT Labs), ivermectin (Alpha Diagnostic), milbemycin oxime (US Phar-
macopeia), moxidectin and selamectin (European Pharmacopoeia).
Drug susceptibility assays
Minimal Inhibitory Concentrations (MIC) were determined in 7H9 broth supplemented with
0.2% glycerol and 10% ADC (M.marinum) or 10% OADC (M. ulcerans) using two-fold serial
dilutions of compounds in triplicate in polystyrene 96-well plates. MTT [3- (4,5-dimethylthia-
zol-2-yl)-2,5-diphenyl tetrazolium bromide] and resazurin were used as the bacterial growth
indicators [11] forM.marinum andM. ulcerans, respectively. ForM.marinum, cultures were
sampled (100 μL) at a cell density of 105 cells/mL and incubated in the presence of the drug for
3 days before addition of 25 μL of MTT (5 mg/mL). After further overnight incubation, 100 μL
of 10% Sodium Lauryl Sulfate (SLS) were added to solubilize the formazan precipitate that indi-
cates bacterial growth and the optical density at 580 nm (OD580) was then measured. In the
case ofM. ulcerans, 100 μL culture samples (OD600 = 0.04) were incubated in the presence of
the drug at 30°C for 8 days before addition of 20 μL of a resazurin solution (0.125 mg/mL), fol-
lowed by overnight incubation at 37°C. Compound activity was determine by fluorescence
measurements (λ = 540/588 nm). The lowest concentration of drug that inhibited 90% of the
MTT or resazurin color conversion (IC90) was used to define MIC values.
M. ulcerans kill-kinetic assay
96-well polystyrene plates containing 200 μL per well of 7H9 broth supplemented with 10%
OADC were inoculated in duplicate withM. ulcerans S1013 to a final OD600 = 0.04 (ca. 10
5
cells/mL). Cultures were grown at 30°C in the presence of 0.5, 2, 4, 8, 16 and 32 μg/mL of sela-
mectin (0.5, 1, 2, 4, 8 and 16 fold the selamectin MIC value, respectively) for 0, 3, 7, 14 and
21 days. At every time point, 100 μL of undiluted and ten-fold serial dilutions were plated on
7H10 agar. Colony-forming units for all plates were determined after 8 weeks of incubation at
30°C.
Results
Comparative in vitro assays of macrocyclic lactones reveal that
milbemycin oxime and selamectin are the most potent againstM.
ulcerans
Eight commercially available macrocyclic lactones used in human and veterinary medicine
were tested in vitro againstM. ulcerans andM.marinum. Milbemycin oxime and selamectin
were the most potent drugs against theM. ulcerans isolates (MIC in 2–4 μg/mL range). Ema-
mectin and moxidectin had intermediate potency (MIC = ca. 32 μg/mL). While it was not pos-
sible to determine minimal inhibitory concentrations for ivermectin (IC90>64 μg/mL), some
inhibitory activity was observed in dose response studies. In contrast, most of the macrocyclic
lactones showed activity againstM.marinum, a faster growing phylogenetic progenitor of
M. ulcerans, with milbemycin oxime being the most potent (Fig 1 and Table 1).
Selamectin for Buruli Ulcer Treatment
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Selamectin killsM. ulcerans
The PK properties of selamectin (described below), together with its high in vitro activity
againstM. ulcerans, strongly indicated it as the most suitable avermectin for further evaluation
as a potential new anti-BU treatment. To further characterize this potential new application,
the in vitro pharmacodynamic (PD) parameters of selamectin were evaluated using kill-kinetic
assays (Fig 2). In vitro kill-kinetic curves for selamectin were obtained by plotting the number
of CFU at every time point for every concentration of the drug (Fig 2A). These experiments
confirmed the MIC and dose-response data determined by reporters of metabolic activity
(resazurin and the MTT; Table 1 and Fig 1) and showed a sharp threshold of bactericidal activ-
ity above the MIC (2 μg/mL). We also used an alternative method to visualize kill kinetics: each
selamectin concentration was multiplied by the time of exposure (CSEL x Tdays) and then
divided by the MIC of selamectin to give the in vitro area under the concentration-time curve
(AUC/MIC ratio), a standard measure of drug exposure (Fig 2B). These analyses showed that
just seven days of exposure were needed to observe the bactericidal activity of selamectin. The
Fig 1. In vitro dose-response of the avermectins againstM. ulcerans andM.marinum. Values are the mean of activities against threeM. ulcerans and
twoM.marinum clinical isolates (see Table 1) performed in triplicate. IC90 and IC50, 90% and 50% reduction of resazurin or MTT color conversion,
respectively.
doi:10.1371/journal.pntd.0003996.g001
Table 1. Antimicrobial activities of macrocyclic lactones againstM. ulcerans andM.marinum.
MIC (μg/mL)a
Strainsb Abamectin Doramectin Emamectin Eprinomectin Ivermectin Milbemycin oxime Moxidectin Selamectin
M. ulcerans S1012 >64 >64 32 >64 >64 8 16 2
S1013 >64 >64 16–32 >64 >64 1–2 >64 1–2
S1047 >64 >64 32 32 >64 4 32 4
M. marinum 1704 8–16 16–32 8 32 8 0.25–0.5 2–4 2–8
1705 8–16 32–64 8 32 8–16 0.25–0.5 2–4 4–8
aAbamectin, doramectin, emamectin, eprinomectin, ivermectin and selamectin are avermectins; moxidectin and milbemycin oxime are milbemycins.
bThe resazurin and the MTT methods were used for M. ulcerans and M. marinum, respectively.
doi:10.1371/journal.pntd.0003996.t001
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AUC/ MIC needed to achieve a bactericidal effect (4-log10 CFU/ml reduction, 99.99% killing)
required AUC/MIC ratios between 10 and 15. These ratios were comparable to those previ-
ously observed forM. tuberculosis [9]. In summary, these studies showed that the activity of
selamectin againstM. ulcerans is exposure-dependent; if a certain concentration is achieved, a
bactericidal effect is observed by increasing the time of exposure but not by increasing dose
Fig 2. Kill kinetics of selamectin againstM. ulcerans S1013.Dose response kill kinetic assays were
plotted based on (A) drug concentration and (B) incubation time. AUC is the concentration of selamectin
multiplied by the time of exposure (AUC = CSEL x Tdays). AUC, area under the curve. SEL, selamectin.
Concentrations are in μg/m.
doi:10.1371/journal.pntd.0003996.g002
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concentrations. This information could have important implications when designing pre-clini-
cal and clinical studies.
Discussion
The family of anthelmintic macrocyclic lactone drugs is one cornerstone of modern parasite
control with annual world sales of US $850 million, indicating a well-established production
and distribution pipeline. These drugs share a poly-cyclic lactone chemical moiety and can be
divided in two sub-families: avermectins and milbemycins [12]. Because members of this fam-
ily of natural products have complex structures and specificity for parasites, only a few have
been commercialized, mostly for veterinary medicine [13]. Ivermectin is used to treat the
human parasitic diseases onchocerciasis and lymphatic filariasis [14]. Moxidectin was also
recently evaluated for these indications in clinical trials [15]. The potential use of ivermectin
for TB treatment is questionable due to its neurotoxicity at high doses and the low exposure
levels achieved using clinically approved doses [16]. We analyzed available literature to com-
pare the pharmacological properties of clinically approved drugs (ivermectin, moxidectin) to
those with best in vitro activities againstM. ulcerans (milbemycin oxime and selamectin)
(Table 2). By integrating this information with in vitro data, we propose selamectin as the
anthelmintic macrocyclic lactone with the highest potential for anti-BU therapy.
In invertebrate nematodes, avermectins specifically bind to glutamate-gated chloride chan-
nels present in nerve and muscle cells, causing paralysis and reduced ability to reproduce. In
general, macrocyclic lactones have a high margin of safety in mammals because P-glycopro-
teins (P-gp) or other types of efflux pumps, highly expressed at the blood–brain barrier, effi-
ciently restrict their penetration into the central nervous system. In fact, dogs lacking the
MDR1 efflux pump, such as collies, have much less tolerance for treatment with an array of
avermectin compounds [29]. In contrast, milbemycin oxime, selamectin, and moxidectin can
be safely administered at therapeutic doses to dogs having a homozygous MDR1 mutation
without any signs of toxicosis [12,28].
PK and toxicological profiles of the clinically used macrocyclic lactones (ivermectin and
moxidectin) have been studied extensively. Using standard dosages for onchocerciasis treat-
ment in humans, ivermectin is extremely well tolerated, effective, orally active, and associated
with long-term safety at the current clinical dose (single dose of 12 mg) [17]. Clinical studies
have shown that it is safe in humans at doses up to 10-fold higher; however, further increased
dosage provokes severe neurotoxicity [18]. To catalyze application of ivermectin’s therapeutic
potential in needy areas throughout the world, Merck & Co. has donated it for over 20 years to
treat patients with river blindness, human onchocerciasis, and lymphatic filariasis [14]. In the
case of moxidectin, single doses of up to 36 mg were safe in humans, but not doses of 54 mg
[23].
The extensive use of macrocyclic lactones in veterinary medicine has generated valuable
pharmacological data that could guide selection of these drugs and facilitate their use in
humans. Milbemycin oxime is a broad-spectrum intestinal anti-parasitic drug used to treat
roundworm, hookworm and tapeworms in cats and dogs; it is also reported to be safer than
ivermectin [12]. Administered routinely at a dose of 0.25 mg/kg, it showed no signs of toxicity
[25]. Although LD50 values after oral administration in dogs are higher than 200 mg/kg, a sin-
gle dose of 3.8 mg/kg was reported to cause reversible neurological signs (trembling, ataxia) in
dogs [30]. In contrast, selamectin has fewer neurological side effects, and can be administered
topically, subcutaneously, or orally to treat a variety of ecto- and endo-parasitic infections in
cats and dogs. It is the drug of choice in avermectin-sensitive collies since it has no adverse
effects [REVOLUTION—fact sheet]. A toxicity study in female CD1 mice found that
Selamectin for Buruli Ulcer Treatment
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selamectin was well tolerated at up to 300 mg/kg body weight (bw), while similar doses of mil-
bemycin oxime were toxic [31]. In the case of milbemycin, doses up to 24 mg/kg bw were safe
in cats and dogs [27] and one study reported that doses up to 94 mg/kg bw were safe in dogs
Table 2. Pharmacokinetic meta-analysis summary of selected avermectins andmilbemycins.
Drug Species Dose (PO unless indicated) Cmax
(ng/mL)
T1/2
(days)
AUC
(ng*h/ mL)
Theoretical
AUC/MICa
Reference
Ivermectin Humans 12 mg (165 μg/kg) 47 nd nd nd [17]
30 mg (fast) (347–541 μg/kg) 85 19 h 2,819 0.04 [18,19]
30 mg (fed) 260 15 h 4,564 0.07
90 mg (1031–1466 μg/kg) 158 19 h 2,910 0.05
120 mg (1404–2000 μg/kg) 247 19 h 4,547 0.07
Dogs 250 μg/kg 132 80 h 5,600 0.09 [19]
Horses 200 μg/kg 44 20 h 3,184 0.05 [20]
Mice (plasma) 0.2 mg/kg 20 9.3 h 573 0.01 [21]
Mice (lung) 0.2 mg/kg 20 nd nd nd
Mice 0.2 mg/kg 89.1 nd 711.7 0.02 [22]
Moxidectin Humans 3 mg (fast) 22.4 33.8 1,442 0.04 [23]
9 mg (fast) 57.9 34.6 3,024 0.10
18 mg (fast) 141 22 5,856 0.18
36 mg (fast) 289 20.2 10,824 0.34
36 mg (fed) 296 25.7 14,976 0.46
Dogs 250 μg/kg 234 621 h 11,800 0.36 ProHeart6 (Product
profile)
Mice 0.2 mg/kg 47.4 nd 643.7 0.02 [22]
Cattle
(plasma)
0.2 mg/kg (s.c) 35.6 8.9 159 (ng.d/
g)
0.004 [24]
Cattle (lung) 0.2 mg/kg (s.c) 63.7 9.1 298 (ng.d/
g)
0.008
Milbemycin
oxime
0.25 mg/kg 79.33 11.09 nd [25]
0.92 mg/kg (once monthly for 3
mo)
353 67.9 6,754.9 3.4 [26]
1.19 mg/kg 152 50.2 3,620 1.8
1.10 mg/kg 199 58.2 5,165 2.6
Selamectin Dogs (male) 6 mg/kg (topical) 12.72 12.14 4,609 2.3 Stronghold (Product
profile)
Dogs (female) 6 mg/kg (topical) 22.65 10.73 8,903 4.45
Mice (plasma) 12 mg/kg 3,714 5.5 62,285.7 31.14 [21]
Mice (lung) 12 mg/kg 7,500 nd nd nd
Rats 10 mg/kg >1,000 10.3 h nd nd Stronghold (Product
profile)
Dogs 24 mg/kg 7,630 45.7 h 227,901 113.95 [27]
24 mg/kg (topical) 86.5 266 15229 7.61
95 mg/kg nd nd nd nd [28]
Cats 24 mg/kg 11,929 97.7 1,109,933 554.97 [27]
24 mg/kg (topical) 5,513 198 743,349 371.67
aTheoretical AUC/MIC was calculated based on our in vitro MIC values of the avermectins against M. ulcerans. MIC values (in ng/mL) used for
calculations were: ivermectin, 64,000; moxidectin, 32,000; milbemycin oxime, 2,000, and selamectin: 2,000.
doi:10.1371/journal.pntd.0003996.t002
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[28]. In addition, a 3-month repeated dose toxicity study in dogs found an oral dose of 40 mg/
kg/day to be safe [28]. Extrapolated to humans, this corresponds to a dose of 2,800 mg/day (for
a 70 kg adult). Confirming this extrapolation, the LD50 in rats and mice could not be demon-
strated and it was higher than 1,600 mg/kg bw [Stronghold (selamectin)—Product profile].
Based on established clinical experience in humans at low dosages, Omansen et al. [10]
chose to study the anti-mycobacterial activities of ivermectin and moxidectin. They reported
MIC values between 4 and 8 μg/mL againstM. ulcerans and inactivity (MIC32 μg/mL)
againstM.marinum. We confirmed the activities of macrocyclic lactones, but found different
specificities against bacterial isolates representing these two species (Table 1 and Fig 1). In con-
trast to analyses reported by Omansen et al. [10], we detected little or no activity of ivermectin
and moxidectin againstM. ulcerans isolates but they were active againstM.marinum strains.
Such discrepancies could reflect variations in methodology. While Omansen et al. used Myco-
bacteria Growth Indicator Tubes (MGIT) and bioluminescence assays for their inhibitions
assays [10], we performed metabolic-based activity assays in liquid cultures grown in 96 well
plates. Subtle differences in methodology are known to play a critical role in quantification of
the anti-mycobacterial activity of ivermectin [16].
Our in vitro results can be integrated with available PK data to predict which drug would be
more suitable for anti-BU therapy. While no human data are available for milbemycin oxime
and selamectin, extensive pharmacological data from animal studies provide valuable informa-
tion to accelerate clinical testing. Standard oral doses (in μg/kg bw range) of ivermectin, moxi-
dectin and milbemycin oxime used to treat helminths in humans only achieve low
concentrations in the plasma (ng/mL range). Area Under the Curve (AUC) values for moxidec-
tin and milbemycin oxime are higher than those of ivermectin, mainly due to their extended
residence times (higher half-life). However, the much higher doses needed to achieve concen-
trations sufficient to kill mycobacteria might not be possible due to toxicity. In contrast, sela-
mectin toxicity is negligible at comparable doses. Standard dose administration of selamectin is
in the mg/kg bw range (versus μg/kg bw) and doses as high as 95 mg/kg bw have been adminis-
tered without any side effects [28]. The ability to deliver such high doses without toxicity is also
reflected in the elevated concentrations of selamectin that can be achieved in the plasma. These
concentrations in the μg/mL range are several fold higher than MIC values againstM. ulcerans
[21,27] which, together with a long half-life (in days), allows for high AUC values. In fact,
AUC/MIC values are the most predictable PK/PD parameter for the anti-mycobacterial activ-
ity of the avermectins [9]. Similarly, AUC/MIC ratios between 10 and 15 are also needed for
bactericidal activity againstM. ulcerans (Fig 2B). Thus, when theoretical AUC/MIC values
were calculated by integrating data from available PK literature with those from our in vitro
data, only selamectin was predicted to have therapeutic activity againstM. ulcerans (Table 2)
(nb, calculations based on the lower in vitroMIC measurement reported by Omamsen et al.
[10] generated the same conclusion). We would also like to point out that when we made corre-
sponding calculations based on in vitroMIC data forM. tuberculosis [9], selamectin would also
be the avermectin of choice for tuberculosis therapy.
A synergistic interaction between rifampicin and ivermectin againstM. ulcerans has also
been reported [10]. Rifampicin is the cornerstone drug for BU treatment. Thus, co-administra-
tion of rifampicin with any synergistic, orally available drug would be ideal. Rifampicin is an
inducer of the P-gp and other transporters. P-gp protects mammals not only by excluding mac-
rocyclic lactones from the central nervous system, but also by limiting the uptake of com-
pounds from the gastrointestinal tract and by promoting their excretion in the liver, kidney,
and intestine. While ivermectin is a good P-gp substrate, thus further reducing available levels
of this drug, selamectin is a poorer P-gp substrate [12,21] and its plasma levels would be
affected to a lesser extent allowing for a potential co-administration with rifampicin.
Selamectin for Buruli Ulcer Treatment
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0003996 August 13, 2015 8 / 10
In summary, drug repositioning is an interesting avenue to provide new treatments for
neglected diseases. We have tested the family of commercially available macrocyclic lactones
againstM. ulcerans andM.marinum and demonstrated that milbemycin oxime and selamectin
are the most active drugs (MIC = 2 μg/mL). Integrating these values with information gathered
in a literature review of the pharmacological properties (toxicity and PK/PD profiles) of iver-
mectin, moxidectin, milbemycin oxime and selamectin, revealed selamectin as the most prom-
ising avermectin candidate for anti-BU treatment. Although selamectin is not approved for use
in humans, extensive information is available on its pharmacological properties in animals,
thus facilitating its progression into clinical trials. These would be warranted if its activity
could be validated using in vivomodels ofM. ulcerans infection. Pre-clinical and clinical devel-
opment of any drug is a task that one research group cannot achieve alone. Thus, we urge col-
laboration among the research communities, pharmaceutical companies, and non-
governmental organizations to validate the potential of macrocyclic lactones, especially sela-
mectin, as a new anti-BU treatment.
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